New blow to AstraZeneca as cancer drug trial is cancelled
11 April 2012
AstraZeneca suffered another hit to its pharmaceuticals pipeline today when the company called off its late-stage trials of a prostate cancer drug.
Britain's second-biggest drugmaker said its oral drug zibotentan was "unlikely to benefit patients" with the type of prostate cancer it was aimed at combating.
The news is another disappointment for AstraZeneca, which wrote off $445 million
(£276.1 million) after abandoning a new children's medicine, Motavizumab, late last year.
The pharma giant was also hit when regulators failed to approve one of its brightest hopes, the heart medicine Brilinta, in December.
